Apigenin reduces the excessive accumulation of lipids induced by palmitic acid via the AMPK signaling pathway in HepG2 cells

JING LU¹, ZHUOQUN MENG¹, BIJUN CHENG¹, MEITONG LIU¹, SIYU TAO² and SHUANG GUAN¹

¹Department of Food Quality and Safety, College of Food Science and Engineering, Jilin University, Changchun, Jilin 130062; ²Department of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China

Received November 7, 2018; Accepted May 23, 2019

DOI: 10.3892/etm.2019.7905

Abstract. In recent years, increasing attention has been paid to diseases caused by excessive accumulation of lipids in the liver with therapeutic agents derived from natural products offering an alternative treatment to conventional therapies. Among these therapeutic agents, apigenin, a natural flavonoid, has been proven to exert various beneficial biological effects. In the present study, the antiadipogenic effects of apigenin in HepG2 cells was investigated. It was demonstrated that the treatment of cells with different concentrations of apigenin for 24 h significantly decreased the palmitic acid-induced increases in total cholesterol (TC) and triglyceride (TG) levels as well as intracellular lipid accumulation. In addition, apigenin increased the phosphorylated-AMP-activated protein kinase (AMPK) levels but decreased the expression levels of 3-hydroxy-3-methylglutaryl CoA reductase, sterol regulatory element-binding protein (SREBP)-1, fatty acid synthase, and SREBP-2 in a concentration-dependent manner. The present findings suggested that apigenin might improve lipid metabolism by activating the AMPK/SREBP pathway to reduce lipid accumulation in the liver.

Introduction

In recent years, obesity has received increasing attention because it leads to various metabolic diseases, such as hyperlipidemia, hypertension, atherosclerosis and type II diabetes mellitus (1). The liver is an important organ associated with lipid metabolism. Notably, increases in lipid metabolism is mainly observed in the liver, which can lead to chronic diseases related to hepatocytes (2). If left untreated, this increase in metabolism can lead to hepatocellular carcinoma therefore, it is necessary to investigate the underlying molecular mechanism (3). Adipogenesis is regulated via a complex process involving coordinated changes in hormone sensitivity and gene expression regulated by various transcription factors (4). The sterol regulatory element-binding protein (SREBP) family of transcription factors have pivotal roles in the regulation of cellular lipid metabolism (5). SREBP-1 mainly regulates the metabolism of fatty acids and triglycerides, whilst SREBP-2 regulates the biosynthesis of cholesterol (6). Fatty acid synthase (FAS), a protein related to fat synthesis, is regulated by SREBP-1 (7). SREBP-2 regulates 3-hydroxy-3-methylglutaryl CoA reductase (HMGCGR) expression and thereby catalyzes the rate-limiting step of cholesterol biosynthesis (8). Furthermore, AMP-activated protein kinase (AMPK) is an important protein involved in energy metabolism and has a significant role in the regulation of fatty acid metabolism. An in vitro study determined that allin attenuates adipogenesis induced by 1,3-dichloropropan-2ol in HepG2 cells by activating the AMPK/SREBP signaling pathway (9). Therefore, it is reasonable to speculate that the AMPK/SREBP pathway might be important for the amelioration of lipogenesis during palmitic acid treatment.

For the development of novel antilipidemic drugs with high efficacy and few adverse effects, attention has gradually shifted to the natural plant flavonoids in recent years. Apigenin, a type of plant flavonoid with the chemical name 4',5,7-dihydroxyflavone, is recognized as a bioactive flavonoid that has antioxidant, anticancer and anti-inflammatory properties that can also lower blood pressure (10-12). In particular, a previous study has demonstrated that apigenin can alleviate myocardial hypertrophy and the hypertrophy-induced glucose and lipid metabolism abnormalities in rats (13). In addition, apigenin alleviates glucose metabolic disorder induced by a high-fat diet in 20-week-old mice (14). It still remains unclear whether apigenin has a hypolipidemic effect, or whether the AMPK/SREBP pathway is the major determinant of anti-adipogenic activity. Palmitic acid is a saturated high-grade fatty acid that is widely distributed in animal and vegetable oils in the form of glycerides, and is commonly used to establish lipotoxic in vitro and in vivo models (15).

The present study established a common hyperlipidemia model by using appropriate doses of palmitic acid to determine whether apigenin lowered lipid levels and, to explore the underlying mechanism in depth.
Materials and methods

Reagents. Palmitic acid and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich; Merck KGaA. The apigenin standard was purchased from Beijing Solarbio Technology Co. The AMPK inhibitor compound C was purchased from Selleck Chemicals LLC. Anti-phospho-AMPK (P-AMPK; Thr172; cat. no. 2535) was purchased from Cell Signaling Technology, Inc., anti-AMPKα1 (cat. no. 10929-2-AP), SREBP-2 (cat. no. 14508-1-AP), FAS (cat. no. 13098-1-AP), HMGC (cat. no. 15353-1-AP) and β-actin (cat. no. 66009-1-lg) were purchased from Proteintech Group Inc., SREBP-1 (cat. no. ab3259) was purchased from Abcam. Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (H + L; cat. no. SA00001-1) and HRP-conjugated goat anti-rabbit IgG (H + L; cat. no. SA00001-2) secondary antibodies were obtained from Proteintech Group Inc.

Cell culture and treatment. Liver cancer HepG2 cells, purchased from the American Type Culture Collection, were cultured in high-glucose DMEM (GE Healthcare Life Sciences) with 10% fetal bovine serum (Clark Bioscience) and 1% penicillin/streptomycin at 37°C in an atmosphere containing 5% CO₂. The cells were dissociated with 0.25% trypsin (w/v) and 0.52 mM EDTA [M&C Gene Technology (Beijing) Ltd.] and routinely sub-cultured at 80% confluency.

Cell cultures were treated with various concentrations of apigenin in DMSO as the carrier solvent. Palmitic acid binds to fatty-acid-free BSA (Beijing Solarbio Science & Technology Co., Ltd.). In brief, palmitic acid was dissolved in 1X PBS and a 250 mM stock solution was obtained following various cycles of incubation in a water bath at 70°C and vortexing. The stock solution was then added to serum-free DMEM containing 5% fatty-acid-free BSA to obtain a 250 µM palmitic acid solution, and the resulting diluted solution was used for the cell treatments (16,17). AMPK inhibitor compound C was diluted with DMSO to a final concentration of 10 µM and was used to verify the signaling pathway.

Cell viability assays. Cells were seeded in 96-well plates at a concentration of 1x10⁴ cells/well (Corning Inc.) and allowed to adhere overnight at 37°C. Cells were then treated with different concentrations of apigenin (0, 20, 40, 80, 160, 320, 640 and 1,280 µM) or palmitic acid (0, 62.5, 125, 250, 500 and 1,000 µM) for 24 h, and 20 µl of MTT (Sigma-Aldrich; Merck KGaA) solution (5 mg/ml in 1% PBS) was added to each well and incubated for 4 h at 37°C prior to the end of the culture. The culture medium was subsequently removed and the formazan crystals were dissolved using 150 µl DMSO/well. Absorbance values at 570 nm were determined using a microplate reader (BioTek Instruments, Inc.).

Oil Red O Staining. HepG2 cells were inoculated at a density of 4x10⁵ cells per well in 6-well plates and cultured with different concentrations of apigenin (10, 20 and 40 µM) and 250 µM palmitic acid for 24 h. Cells were then washed twice with cold 1X PBS and fixed with 4% paraformaldehyde for 40 min at 37°C. Subsequently, the residual paraformaldehyde was washed with double-distilled water, and cells were incubated with 60% isopropanol for 3-5 sec. Cells were then stained with freshly prepared 0.5% Oil Red O solution in 60% isopropanol for 1 h at 37°C in the dark. Lipid droplets in the cells were observed and imaged using a bright-field microscope (Olympus Corporation) at a magnification of x400. In addition, the accumulated lipids were extracted with 100% isopropanol for 3-5 min at room temperature, and the absorbance at 570 nm was determined using a microplate reader.

Triglyceride (TG) and total cholesterol (TC) assays. HepG2 cells were inoculated at a density of 4x10⁵ cells/well in 6-well plates and pretreated with 10 µM AMPK inhibitor compound C for 1 h at 37°C then cultured with different concentrations of apigenin (10, 20 and 40 µM) and 250 µM palmitic acid for 24 h at 37°C in a culture chamber with 5% CO₂. The intracellular TC and TG contents were measured using a TC assay kit (cat. no. E1015; Applygen Technologies Inc.) and a TG assay kit (cat. no. E1013; Applygen Technologies Inc.) according to the manufacturer’s instructions. The absorbance values were measured at 570 nm. Bicinchoninic acid (BCA) protein quantitative kit (Beyotime Institute of Biotechnology) was used to determine the protein concentration of the samples, and the absorbance value of the proteins was measured at 562 nm. The intracellular TC and TG contents are presented as µM/mg cellular protein.

Western blot analysis. HepG2 cells were seeded in 6-well plates at a concentration of 6x10⁵ cells per well and pretreated with 10 µM AMPK inhibitor compound C for 1 h and then cultured with different concentrations of apigenin (10, 20 and 40 µM) and 250 µM palmitic acid (16,17). The cell pellets were lysed on ice for 30 min in RIPA buffer (Beyotime Institute of Biotechnology) supplemented with 1:100 PMSF (Beijing Solarbio Science & Technology Co., Ltd.) according to the manufacturer’s specifications and centrifuged at 14,000 x g at 4°C for 8 min. The supernatant was then collected and the protein concentration was determined using a BCA protein concentration assay kit (Beyotime Institute of Biotechnology). An equal amount of protein extract (80 µg) was denatured in the sample buffer (Bio-Rad Laboratories, Inc.) at 98°C for 10 min and subsequently separated via 8% SDS-PAGE and then transferred to polyvinylidene fluoride membranes. The membranes were blocked with 3% BSA in Tris-buffered saline containing 0.1% Tween 20 (TBST) buffer for 4 h at room temperature. Subsequently, the membranes were incubated overnight at 4°C with primary antibodies anti-phosphorylated (P)-AMPK (1:500), anti-AMPK (1:500) anti-SREBP-1 (1:300), anti-FAS (1:800), anti-SREBP-2 (1:500), anti-HMGCR (1:800) and anti-β-actin (1:800 dilution). Following incubation with the primary antibodies, the membranes were subjected to three 15-min washes with TBST and then incubated with horseradish peroxidase-conjugated secondary anti-mouse antibody and anti-rabbit antibody (1:3,000 dilution) at room temperature for 2 h. Protein bands were visualized using the Enhanced Chemiluminescence Plus substrate (Azure Biosystems, Inc.). All Western blot assays were performed at least three times. The resulting images were analyzed using the ImageJ software (version 1.51; National Institutes of Health) with β-actin as the loading control.

Statistical analysis. Data were processed using SPSS v18.0 statistical software (SPSS Inc.), and the measurement data
were expressed as the mean ± standard deviation. Statistical analysis was performed by one-way analysis of variance with Tukey’s test and Dunnett’s test used for post hoc analysis. Histograms were plotted by Prism software v5.0 (GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

Effects of apigenin and palmitic acid on cell viability. To analyze the effect of apigenin and palmitic acid on the viability of HepG2 cells, the cells were exposed to different concentrations of apigenin or palmitic acid for 24 h. Results demonstrated that apigenin significantly decreased the viability of HepG2 cells at concentrations from 320 to 1,280 µM (P<0.01; Fig. 1A), and palmitic acid significantly decreased the viability of HepG2 cells at concentrations from 500 to 1,000 µM (P<0.01; Fig. 1B).

Effects of apigenin on lipid accumulation in palmitic acid-treated HepG2 cells. The cells were exposed to different concentrations of palmitic acid (150, 250 and 350 µM) for 24 h and cellular TC and TG contents were subsequently measured. The results demonstrated that the intracellular TC and TG levels were significantly elevated when cells were treated with 250 and 350 µM palmitic acid compared with control cells (P<0.05; Fig. 1C and D). The accumulation of lipid droplets in cells was measured by Oil red O staining. The results indicated that the lipid content in HepG2 cells treated with 250 µM palmitic acid was increased significantly compared with the control cells. In addition, 20 and 40 µM apigenin treatment significantly decreased the level of the lipid content compared with treatment with palmitic acid alone (P<0.05; Fig. 1E and F).

To verify the Oil red O staining results, the cellular TC and TG contents were measured. Results demonstrated that the intracellular TC and TG levels were significantly elevated when cells were treated with 250 µM palmitic acid compared with the control cells (P<0.01; Fig. 1G and H). However, treatment with 250 µM palmitic acid and different concentrations of apigenin (10, 20 and 40 µM) significantly suppressed intracellular TC and TG levels in a concentration-dependent manner (P<0.01; Fig. 1G and H).

Effects of apigenin on the AMPK and P-AMPK proteins in palmitic acid-induced HepG2 cells. The activity of AMPK is closely associated with phosphorylation of the Thr172 site in the α subunit (P-AMPKα1). Therefore, the activity of AMPK can be evaluated by measuring the levels of P-AMPKα protein. Results demonstrated that the P-AMPK/AMPK ratio in the cells treated with 250 µM palmitic acid was significantly lower than in the normal group (P<0.01; Fig. 2A). However, the treatment of HepG2 cells with 250 µM palmitic acid and different concentrations of apigenin (10, 20 and 40 µM)
significantly increased AMPK phosphorylation (P<0.01; Fig. 2A). The P-AMPK/β-actin ratio in the cells treated with 250 µM palmitic acid and different concentrations of apigenin (10, 20 and 40 µM) produced the same results as aforementioned (P<0.01; Fig. 2B).

Effects of apigenin on the AMPK/SREBP signaling pathway in palmitic acid-treated HepG2 cells. To investigate the mechanism underlying the apigenin-mediated inhibition of lipid production and regulation of the AMPK signaling pathway in HepG2 cells, the expression levels of proteins associated with fatty acid synthesis and cholesterol synthesis were determined.

Results demonstrated that compared with the control cells, the levels of SREBP-1 (P<0.01; Fig. 2B) and FAS (P<0.05; Fig. 2C) increased significantly following treatment with 250 µM palmitic acid, whereas the levels of SREBP-1 and FAS were decreased by apigenin in a concentration-dependent manner (P<0.01; Fig. 2B and C). SREBP-2 and HMGCR protein expression increased significantly upon treatment with 250 µM palmitic acid compared with the control (P<0.01; Fig. 2D and E). However, HepG2 cells treated with 250 µM palmitic acid and different concentrations of apigenin (10, 20 and 40 µM) inhibited the upregulation of SREBP-2 and HMGCR protein expression (P<0.01; Fig. 2D and E).

Effects of compound C on lipid accumulation and AMPK expression in palmitic acid-treated HepG2 cells. To further validate the previous findings, the intracellular TC and TG contents were measured following pretreatment with 10 µM compound C for 1 h. The compound C treatment significantly reversed the apigenin-induced reductions in lipid accumulation and led to increases in TC and TG contents (P<0.01; Fig. 3A and B).

In addition, the protein expression of AMPK and P-AMPK were examined. The increase in P-AMPK/AMPK ratio induced by apigenin was reversed by pretreatment with compound C in HepG2 cells (P<0.01; Fig. 3C and D). These results indicated that apigenin activated the AMPK signaling pathway in HepG2 cells.

The present findings indicated that apigenin effectively inhibited the effects of palmitic acid-induced lipid accumulation via the AMPK/SREBP signaling pathway in HepG2 cells (Fig. 4).

Discussion

Numerous flavonoids display anti-obesity and hypolipidemic effects in animals and humans. It has been demonstrated that apigenin exerts anticancer, anti-inflammatory and hypotensive effects (10-12). Previous studies have determined that apigenin reduces the accumulation of intracellular lipids in 3T3-L1 cells (18), and also attenuates atherogenesis via upregulating ATP binding cassette subfamily A member 1-mediated cholesterol efflux and by inhibiting inflammation (19). Apigenin suppresses adipogenesis through the downregulation of peroxisome proliferator activated receptor-γ function by activating AMPK in 3T3-L1 cells (4). Nonetheless, the regulatory mechanism underlying the apigenin-mediated suppression of lipid accumulation has yet to be fully identified.
The present study identified that apigenin served an essential role in the reduction of excessive lipid accumulation induced by palmitic acid in HepG2 cells. Results demonstrated that apigenin was not toxic to HepG2 cells at concentrations of <320 µM, whilst palmitic acid exhibited no apparent toxicity to HepG2 cells at concentrations <250 µM. Of note, apigenin has been determined to be cytotoxic to 3T3-L1 cells at concentrations as low as 10 µM (4), whilst palmitic acid is cytotoxic to HepG2 cells at concentrations as low as 200 µM, which is in line with the present study (20). The discrepancies might be due to differences between cell lines or assay systems with further investigation required to elucidate a clear explanation.
A previous study demonstrated that apigenin is a poorly soluble bioactive compound/nutraceutical with a poor bioavailability upon oral administration (21). The oral bioavailability of apigenin is relatively poor due to its low lipid (0.001-1.63 mg/ml in nonpolar solvents) and water (2.16 µg/ml in water) solubility, which has severely limited its development for clinical applications (22,23). However, there are a number of methods in which the bioavailability of apigenin can be improved, including utilizing spray-drying techniques and apigenin-loaded polymeric micelles (24,25). Therefore, future research into apigenin should not only take into consideration the lower reported toxic dose but also try to improve the oral bioavailability of apigenin.

To further elucidate the molecular mechanism underlying the apigenin-mediated suppression of adipogenesis, the present study investigated the activation of AMPK, which is an important kinase that regulates energy homeostasis. This key protein is involved in various cell signal transduction pathways, senses the intracellular energy state and has an important role in the regulation of glucose and lipid metabolism (26,27). AMPK activation reportedly leads to changes in obesity and has been linked to obesity prevention (28,29). Therefore, the pharmacological activity of AMPK is expected to have an important role in the study of apigenin-induced liver lipid accumulation reduction. This study identified that cotreatment of apigenin (10, 20 and 40 µM) and 250 µM palmitic acid led to a dose-dependent upregulation of the P-AMPK/AMPK ratio compared with the group treated with 250 µM palmitic acid alone. This indicated that apigenin activated AMPK phosphorylation in the palmitic acid-induced HepG2 cells. Thus, to further validate the experimental results, cells were treated with the AMPK inhibitor compound C. The increase in the P-AMPK/AMPK ratio induced by apigenin in HepG2 cells was inhibited by pretreatment with compound C in HepG2 cells. Therefore, apigenin inhibited excessive lipid accumulation induced by palmitic acid by activating AMPK phosphorylation.

Changes in proteins associated with the AMPK/SREBP pathway were investigated to fully elucidate the hypolipidemic mechanism of apigenin. Apigenin treatment activates AMPK thereby further inhibiting the synthesis of fatty acids and cholesterol (8). It has been demonstrated that AMPK inhibits SREBP-1 and SREBP-2 and thereby reduces the synthesis of cholesterol, fatty acids, and triglycerides in the liver (30). Lipid production in the liver is mainly regulated by SREBP-1, which is a crucial regulatory factor in fatty acid synthesis. SREBP-1 regulates the expression of other genes involved in TG synthesis, such as FAS (31). SREBP-1c inhibition reduces the expression of FAS and alleviates fat-containing liver lesions in mice (32). Similarly, SREBP-2 is mainly involved in the regulation of cholesterol synthesis, and HMGR is a target gene of SREBP-2 (33). Decreased SREBP-2 activity can lead to reduced HMGR expression. In addition, studies have identified that the presence of free cholesterol significantly increases the levels of SREBP-2 and its target gene HMGR in the livers of hyperlipidemic mice (34,35). These studies indicate that the changes in the levels of proteins in the AMPK/SREBP pathway are correlated with the TC and TG levels. In the present study, compared with palmitic acid treatment alone, cotreatment with different concentrations of apigenin (10, 20 and 40 µM) and palmitic acid significantly suppressed TC and TG levels, as well as SREBP-1, FAS, SREBP-2, and HMGR protein expression. Taken together, these results demonstrated that apigenin decreased lipid levels and alleviated the palmitic acid-induced accumulation of lipids in HepG2 cells by activating the AMPK/SREBP signaling pathway.

In summary, apigenin alleviated the palmitic acid-induced increases in lipid accumulation in HepG2 cells thereby reducing the lipid content. The underlying mechanism might be associated with the activation of the intracellular AMPK/SREBP signaling pathway. These findings provide a novel approach for the development of natural hypolipidemic drugs to prevent lipid accumulation.

Acknowledgements

Not applicable.

Funding

This study was funded by the Graduate Innovation Fund of Jilin University, China (grant no. 419020201348).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

SG, JL, ZM and BC conceived the study and participated in its design. ZM and BC performed the experiments. ZM, BC, ML and ST participated in the acquisition and interpretation of the data. SG, JL, ZM and BC participated in manuscript drafting. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Williams JA, Manley S and Ding WX: New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases. World J Gastroenterol 20: 12908-12933, 2014.
2. Wan Y, Liu LY, Hong ZF and Peng J: Ethanol extract of Cirsium japonicum attenuates hepatic lipid accumulation via AMPK activation in human HepG2 cells. Exp Ther Med 8: 79-84, 2014.
3. Zhang M, Yuan Y, Wang Q, Li X, Men J and Lin M: The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα. Biosci Rep 38: BSR20180644, 2018.
4. Ono M and Fujimori K: Antiadipogenic effect of dietary apigenin through activation of AMPK in 3T3-L1 cells. J Agric Food Chem 59: 13346-13352, 2011.
5. Xiao X and Song BL: SREBP: A novel therapeutic target. Acta Biochim Biophys Sin 45: 2-10, 2013.
6. Shimano H: Sterol regulatory element binding proteins (SREBPs): Transcriptional regulators of lipid synthetic genes. Prog Lipid Res 40: 439-452, 2001.
7. Wong TY, Lin SM and Leung LC: The flavone luteolin suppresses SREBP-2 expression and post-translational activation in hepatic cells. PLoS One 10: e0135637, 2015.
8. Motttillo EP, Desjardins EM, Crane JD, Smith BK, Green AE, Ducommun S, Henrikssen TI, Rebalka IA, Razi A, Sakamoto K, et al: Lack of adipocyte AMPK exacerabtes insulin resistance and hepatic steatosis through brown and beige adipose tissue function. Cell Metab 24: 118-129, 2016.
9. Lu J, Cheng B, Meng Z, Sun M, Fang B, Li T, Sun M, Liu M and Guan S: Altinian attenuates 1,3-dichloro-2-propanol-induced lipo-genesis in HepG2 cells through activation of the AMPK-activated protein kinase-dependent pathway. Life Sci 915: 19-24, 2018.
10. Jordan S, O’Neill C and O’Brien NM: Effects of apigenin, lycopene and astaxanthin on 7 beta-hydroxycholesterol-induced apoptosis and Akt phosphorylation in U937 cells. Br J Nutr 100: 287-296, 2008.
11. Tong X and Pelling J: Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. Anticancer Agents Med Chem 13: 971-978, 2013.
12. Zhu ZY, Gao T, Huang Y, Xue J and Xie ML: Apigenin ameliorates hypertension-induced cardiac hypertrophy and down-regulates cardiac hypoxia inducible factor-1 in rats. Food Funct 7: 3992-3998, 2016.
13. Ren B, Qin W, Wu F, Wang S, Pan C, Wang L, Zeng B, Ma S and Liang J: Apigenin and naringenin regulate glucose and lipid metabolism, and ameliorate vascular dysfunction in type 2 diabetic rats. Eur J Pharmacol 773: 13-23, 2016.
14. Escande C, Nin V, Price NL, Capellini V, Gomes AP, Barbosa MT, O’Neill L, White TA, Sinclair DA and Chini EN: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes 62: 1084-1093, 2013.
15. Poitout V and Robertson RP: Glucolipotoxicity: Fuel excess and beta-cell dysfunction. Endocr Rev 29: 351-366, 2008.
16. Mayer CM and Belsham DD: Palmitate acid attenuates insulin resistance and beta-cell dysfunction. Endocr Rev 144: 5179-5183, 2003.
17. Long YC and Zierath JR: AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116: 1776-1783, 2006.
18. Ruderman N and Pretinki M: AMP kinase and malonyl-CoA: Targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3: 340-351, 2004.
19. Sun X, Duan X, Wang C, Liu Z, Sun P, Huo X, Ma X, Sun H, Liu K and Meng Q: Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice. Eur J Pharmacol 5: 75-82, 2017.
20. Frederico MJ, Vitto MF, Cesconetto PA, Engelmann J, De Souza DR, Luz G, Pinho RA, Ropelle ER, Cintra DE and de Souza CT: Short-term inhibition of SREBP-1c expression reversed dietinduced nonalcoholic fatty liver disease in mice. Scand J Gastroenterol 46: 1381-1388, 2011.
21. Sakakura Y, Shimano H, Sone H, Takahashi A, Inoue N, Toyoshima H, Suzuki S and Yamada N: Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochem Biophys Res Commun 286: 176-183, 2001.
22. Block MJ: American chemical society. Chemycyclopedia 2000: 106-107, 2001.
23. Zhang J, Liu D, Huang Y, Gao Y and Qian S: Biopharmaceutics classification and intestinal absorption study of apigenin. Int J Pharm 436: 311-317, 2012.
24. Altamimi MA, Elzayat EM, Alshehri SM, Mohsin K, Ibrahim MA, Al Meanazal OT, Shakerel F, Alanazi FK and Alsarra IA: Utilizing spray drying technique to improve oral bioavailability of apigenin. Adv Powder Technol 29: 1676-1684, 2018.
25. Zhai YJ, Guo SS, Liu CH, Yang CF, Dou JF, Li LB and Zhai GX: Preparation and in vitro evaluation of apigenin-loaded polymeric micelles. Colloids Surfaces A: Physicochemical Engineering Aspects 429: 24-30, 2013.
26. Hardie DG: Minireview: The AMP-activated protein kinase cascade: The key sensor of cellular energy status. Endocrinology 144: 5179-5183, 2003.
27. Carling D: The AMP-activated protein kinase cascade: a unifying system for energy control. Trends Biochem Sci 29: 18-24, 2004.
28. Kang MC, Ding Y, Kim EA, Choi YK, de Araujo T, Heo SJ and Lee SH: Indole derivatives isolated from Brown alga Sargassum thunbergii inhibit Adipogenesis through AMPK activation in 3T3-L1 preadipocytes. Mar Drugs 15: E119, 2017.
29. Escande C, Nin V, Price NL, Capellini V, Gomes AP, Barbosa MT, O’Neill L, White TA, Sinclair DA and Chini EN: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes 62: 1084-1093, 2013.
30. Poitout V and Robertson RP: Glucolipotoxicity: Fuel excess and beta-cell dysfunction. Endocr Rev 29: 351-366, 2008.
31. Mayer CM and Belsham DD: Palmitate acid attenuates insulin resistance and beta-cell dysfunction. Endocr Rev 29: 351-366, 2008.
32. Long YC and Zierath JR: AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116: 1776-1783, 2006.
33. Ruderman N and Pretinki M: AMP kinase and malonyl-CoA: Targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3: 340-351, 2004.
34. Sun X, Duan X, Wang C, Liu Z, Sun P, Huo X, Ma X, Sun H, Liu K and Meng Q: Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice. Eur J Pharmacol 5: 75-82, 2017.
35. Frederico MJ, Vitto MF, Cesconetto PA, Engelmann J, De Souza DR, Luz G, Pinho RA, Ropelle ER, Cintra DE and de Souza CT: Short-term inhibition of SREBP-1c expression reversed dietinduced nonalcoholic fatty liver disease in mice. Scand J Gastroenterol 46: 1381-1388, 2011.
36. Sakakura Y, Shimano H, Sone H, Takahashi A, Inoue N, Toyoshima H, Suzuki S and Yamada N: Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochem Biophys Res Commun 286: 176-183, 2001.
37. Caballero F, Fernandez A, De-Lacy AM, Fernandez-Checa JC, Caballera J and Garcia-Ruiz C: Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol 50: 789-796, 2009.
38. Sun JH, Liu X, Cong LX, Li H, Zhang CY, Chen JG and Wang CM: Metabolomics study of therapeutic mechanism of Schisandra Chinesisignans in diet-induced hyperlipidemia mice. Lipids Health Dis 16: 145, 2017.